Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olanzapine

FDA-approved product (tablet, oral), marketed as Olanzapine, Zyprexa, Zyprexa Zydis and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olanzapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Major depressive disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olanzapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olanzapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

    NCT06338683 · start 2024-03-20

    Registered record
    Registry ID
    NCT06338683
    Conditions
    Advanced Cancer; Olanzapine; Progression Free Survival
    Interventions
    Olanzapine 2.5 MG; Standard anti-tumor treatment; Nutritional advice
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-03-20
    Completion
    2028-03-20
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Olanzapine; Progression Free Survival
    InterventionOlanzapine 2.5 MG; Standard anti-tumor treatment; Nutritional advice
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Olanzapine After Intranasal and Intramuscular Administration

    NCT06600477 · start 2023-10-16

    Registered record
    Registry ID
    NCT06600477
    Conditions
    Healthy
    Interventions
    olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-10-16
    Completion
    2023-11-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionolanzapine
    PhasePhase 1
    Registry statusCompleted

  • Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and

    NCT06949657 · start 2023-10-13

    Registered record
    Registry ID
    NCT06949657
    Conditions
    Schizophrenia Disorders; Cognitive Impairment; Acceptance and Commitment Therapy
    Interventions
    the conventional treatment group; the ACT group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2023-10-13
    Completion
    2024-09-19
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Disorders; Cognitive Impairment; Acceptance and Commitment Therapy
    Interventionthe conventional treatment group; the ACT group
    PhaseNot applicable
    Registry statusTerminated

  • Anti-emetic Prophylaxis With or Without Dexamethasone

    NCT05242874 · start 2022-02-01

    Registered record
    Registry ID
    NCT05242874
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen; Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2023-08-15
    Enrolment
    442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionFosaprepitant, tropisetron, and olanzapine-based antiemetic regimen; Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
    PhasePhase 3
    Registry statusCompleted

  • The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

    NCT05202275 · start 2020-12-01

    Registered record
    Registry ID
    NCT05202275
    Conditions
    Nausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect
    Interventions
    Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-12-01
    Completion
    2023-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect
    InterventionOlanzapine
    PhasePhase 2
    Registry statusUnknown

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    NCT04312503 · start 2020-07-13

    Registered record
    Registry ID
    NCT04312503
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2022-10-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    PhaseNot recorded
    Registry statusCompleted

  • Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients

    NCT04898270 · start 2019-12-19

    Registered record
    Registry ID
    NCT04898270
    Conditions
    Schizophrenia; Psychosis; Metabolic Syndrome; Flupentixol; Antipsychotic Agents; Central Nervous System Diseases; Clinical Therapy; Olanzapine; Quetiapine
    Interventions
    Flupentixol; Multi-acting receptor-targeted antipsychotics (MARTAs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-19
    Completion
    2021-04-20
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychosis; Metabolic Syndrome; Flupentixol +5 more
    InterventionFlupentixol; Multi-acting receptor-targeted antipsychotics (MARTAs)
    PhasePhase 4
    Registry statusCompleted

  • The Effect of CORT118335 on Olanzapine-Induced Weight Gain

    NCT03877562 · start 2019-04-01

    Registered record
    Registry ID
    NCT03877562
    Conditions
    Antipsychotic-induced Weight Gain
    Interventions
    Olanzapine; CORT118335; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2020-03-25
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntipsychotic-induced Weight Gain
    InterventionOlanzapine; CORT118335; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

    NCT03876938 · start 2019-03-01

    Registered record
    Registry ID
    NCT03876938
    Conditions
    Antiemetic for Highly Emetogenic Chemotherapy
    Interventions
    aprepitant; olanzapine 10 mg; olanzapine 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-03-01
    Completion
    2020-12
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiemetic for Highly Emetogenic Chemotherapy
    Interventionaprepitant; olanzapine 10 mg; olanzapine 5 mg
    PhasePhase 3
    Registry statusUnknown

  • A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    NCT03568500 · start 2018-05-21

    Registered record
    Registry ID
    NCT03568500
    Conditions
    Schizophrenia; Schizoaffective Disorder; First Episode Psychosis
    Interventions
    Digital Medicine System; Aripiprazole; Olanzapine; Quetiapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; First Episode Psychosis
    InterventionDigital Medicine System; Aripiprazole; Olanzapine; Quetiapine +1 more
    PhasePhase 4
    Registry statusCompleted

  • Oral Olanzapine Versus Haloperidol or Diazepam

    NCT03246620 · start 2017-09-01

    Registered record
    Registry ID
    NCT03246620
    Conditions
    Acute Agitation; Behavioural Emergency
    Interventions
    Olanzapine oro-dispersible 5Mg Tab; Haloperidol 2Mg encapsulated Tab; Diazepam 2Mg encapsulated Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-09-01
    Completion
    2018-06-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Agitation; Behavioural Emergency
    InterventionOlanzapine oro-dispersible 5Mg Tab; Haloperidol 2Mg encapsulated Tab; Diazepam 2Mg encapsulated Tab
    PhasePhase 4
    Registry statusTerminated

  • A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

    NCT02694328 · start 2016-03-02

    Registered record
    Registry ID
    NCT02694328
    Conditions
    Schizophrenia
    Interventions
    ALKS 3831; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-02
    Completion
    2018-11-07
    Enrolment
    561

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionALKS 3831; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

    NCT01893229 · start 2013-09

    Registered record
    Registry ID
    NCT01893229
    Conditions
    Bipolar Disorder
    Interventions
    Lithium; Valproate; Oxcarbazepine; Quetiapine; Olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionLithium; Valproate; Oxcarbazepine; Quetiapine +2 more
    PhasePhase 4
    Registry statusUnknown

  • Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

    NCT02447835 · start 2012-08

    Registered record
    Registry ID
    NCT02447835
    Conditions
    Normal Non-fluency
    Interventions
    Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNormal Non-fluency
    InterventionOlanzapine
    PhasePhase 1
    Registry statusCompleted